« Return to News | CROs/Service Providers | Miscellaneous

The CenterWatch Monthly, March 2012

Thursday, March 1, 2012 06:05 AM

Living in a post-M&A world of CROs

The CRO industry has been reshaped during the past year by a wave of acquisitions. Large-scale mergers, led by INC Research and inVentiv, have given mid-tier CROs the global scale needed to compete against their rivals for the biggest outsourcing opportunities. At the same time, the industry has consolidated as major CROs continue to make small, strategic acquisitions that can fill gaps in their…

 

Sites struggle with burden, blessing of multiple technologies

With pressure from sponsors and CROs to perform more efficiently and effectively, sites must depend on a variety of system requirements while keeping pace with evolving technology solutions. Sites typically adapt to the technology needs of sponsors and CROs, juggling multiple system requirements across multiple clinical trials, which results in…

 

Eye on Emergent

To reduce development risks and time before products come to market, Emergent BioSolutions uses an acquisition and licensing strategy to procure biodefense and commercial product candidates capable of stimulating a prophylactic or therapeutic immune response...

 

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.